Uber stock slips as SpotHero acquisition-talk report emerges in year-end trade
31 December 2025
1 min read

Uber stock slips as SpotHero acquisition-talk report emerges in year-end trade

NEW YORK, December 31, 2025, 14:53 ET — Regular session

  • Uber shares traded slightly lower after a report said it has held talks to acquire parking app SpotHero.
  • The move keeps focus on Uber’s push to add services beyond ride-hailing and delivery.
  • Traders are watching for deal clarity and the next earnings update as 2025 winds down.

Uber Technologies (UBER.N) shares were down about 0.3% at $81.87 in afternoon trade on Wednesday, after moving between $81.60 and $82.48, following a report the company has been in talks to acquire parking reservation app SpotHero. The Information said SpotHero has raised more than $110 million and was most recently valued at about $290 million, citing PitchBook data. 1

The report matters now because Uber is under pressure to show it can keep growing without leaning solely on ride-hailing. Investors have rewarded companies that can add higher-frequency services and keep users inside a single app.

It also lands as markets wrap up the year and traders reset positioning into 2026. In thin holiday trading, deal chatter can grab more attention than it might in a busier week.

SpotHero lets drivers find, reserve and prepay for parking, and the company says it is available in more than 400 cities in the United States and Canada. SpotHero also says it has helped park 100 million cars since 2011. 2

For Uber, parking is a logical adjacent service for people who drive themselves, not just those who take rides. A tie-up could also help Uber pitch itself as a broader mobility marketplace rather than a single-purpose ride-hailing app.

Uber’s move came as Wall Street drifted lower in the final session of 2025. “I do not expect that the last few days will have so much bearing on the performance of the next year,” said Giuseppe Sette, co-founder and president of Reflexivity. 3

Ride-hailing rival Lyft was up about 0.2%, while delivery peer DoorDash was down about 0.2% in afternoon trading.

Investors will now look for any confirmation of talks, potential deal terms and how Uber would integrate parking into its existing products. Any acquisition would also raise questions about whether Uber wants to expand with small “tuck-in” deals or pursue bigger moves.

Macro catalysts remain close behind. The Federal Reserve’s next policy meeting is scheduled for Jan. 27-28, and rate expectations have been a key driver of valuations across consumer and technology stocks. 4

On the company calendar, Nasdaq lists Feb. 4 as an estimated date for Uber’s next earnings report. 5

Uber’s last quarterly update projected fourth-quarter gross bookings — the total dollar value of rides, deliveries and other transactions on its platform — of $52.25 billion to $53.75 billion. It forecast adjusted EBITDA, a closely watched profit metric that excludes some costs, of $2.41 billion to $2.51 billion. 6

Stock Market Today

IBM stock price jumps 3% into weekend as Confluent vote and dividend date near

IBM stock price jumps 3% into weekend as Confluent vote and dividend date near

7 February 2026
New York, February 7, 2026, 15:20 EST — Market closed. International Business Machines Corp shares closed up 3.12% on Friday at $298.93, giving the stock a firmer finish ahead of Monday’s reopen after a choppy week in U.S. tech. The bounce mattered because it landed on a broad risk-on day that pushed the Dow to a first close above 50,000, after three sessions of losses fueled by anxiety over whether big AI budgets will pay off. “There’s enough evidence that there’s real demand for AI products,” Baird investment strategy analyst Ross Mayfield said. 1 Macro data also helped set the
AstraZeneca stock price: What could move AZN next week as earnings loom

AstraZeneca stock price: What could move AZN next week as earnings loom

7 February 2026
AstraZeneca shares rose Friday, closing at $193.03 in New York, up 3.1%, and 14,104p in London, up 0.9%. The company reports full-year and Q4 2025 results Tuesday, with investors focused on 2026 guidance. The FDA this week issued a complete response letter for a subcutaneous Saphnelo filing, while granting Priority Review to Datroway for breast cancer. AstraZeneca recently shifted its primary U.S. listing to the NYSE.
F&G stock drops nearly 3% as Fidelity National’s share distribution hits on Dec. 31
Previous Story

F&G stock drops nearly 3% as Fidelity National’s share distribution hits on Dec. 31

Cytokinetics stock jumps today as CYTK traders focus on Myqorzo launch and insider filing
Next Story

Cytokinetics stock jumps today as CYTK traders focus on Myqorzo launch and insider filing

Go toTop